341: Julie Gerberding | Answering Your COVID-19 Questions

Vaccine Development

The development of a COVID-19 vaccine presents numerous challenges and complexities. Julie Gerberding explains that while treatments for COVID-19 may be available sooner due to the immediate need to address severe cases, a fully approved vaccine could take many months to develop 1. She notes that investigational vaccines might be used for high-risk groups like healthcare workers before full approval. This approach mirrors the use of the Ebola vaccine in the Democratic Republic of the Congo 1.

It's possible with coronavirus that before we have an approved vaccine for coronavirus, that we have an investigational vaccine that appears to be safe and useful.

--- Julie Gerberding

Additionally, convalescent plasma trials are underway, offering a faster alternative to traditional vaccines by using antibodies from recovered patients to potentially confer immunity 2.

   

Treatment Research

Research into COVID-19 treatments is marked by a balance between urgency and safety. Julie Gerberding highlights the need for rapid testing of treatments for critically ill patients, emphasizing that doing nothing could be a death sentence 3. However, she stresses that vaccines require more extensive testing due to their use in healthy populations.

Treatments are one thing for sick people. Vaccines for healthy people are another, and the timelines are very different.

--- Julie Gerberding

Convalescent plasma, a form of passive immunity, is being studied as a potential treatment, with hopes that it could enhance the body's natural defenses and speed recovery 2.

   

Understanding Immunity

Understanding immunity post-COVID-19 infection is crucial for future prevention strategies. Julie Gerberding points out that while antibodies develop quickly in infected individuals, it's unclear if they prevent reinfection or how long immunity lasts 4. This uncertainty complicates efforts to predict the virus's future behavior and the effectiveness of vaccines.

We do know that people develop antibodies, so that's the good news. But what we don't know is do those antibodies actually prevent the infection the next time you're exposed.

--- Julie Gerberding

She also cautions against over-reliance on antibody testing for economic reopening, as the tests' accuracy and implications for immunity remain uncertain 5.